Khan Khurshid Ahmed, Abbasi Ahmed Nadeem, Ali Nasir
Department of Oncology, The Aga Khan University Hospital, Karachi.
J Coll Physicians Surg Pak. 2014 Dec;24(12):935-9.
Anaplastic Oligodendroglioma / Anaplastic Oligoastrocytoma (AO/AOA) is a WHO Grade-III primary brain tumor. These tumors comprise about 5 - 10% of all gliomas, which make them the third most common primary brain tumors after glioblastoma multiforme and astrocytomas. For many years standard of treatment remained Maximum Safe Resection (MSR) followed by Radiotherapy (RT). These tumors have also been known to be sensitive to alkylator-based chemotherapy particularly the subset having 1p/19q co-deletion signature. There is robust data showing that these tumors are responsive to chemotherapy in recurrent or progressive setting. Recently, up front chemotherapy has been added to standard post-surgery RT. It has been found that subset of AO/AOA having 1p/19q co-deletion responded very well to the addition of chemotherapy. This substantial benefit in terms of median Overall Survival (OS) and median Progression Free Survival (PFS) have intrigued the personalized treatment of AO/AOA on the basis of molecular signature markers.
间变性少突胶质细胞瘤/间变性少突星形细胞瘤（AO/AOA）是一种世界卫生组织III级原发性脑肿瘤。这些肿瘤约占所有胶质瘤的5%-10%，使其成为继多形性胶质母细胞瘤和星形细胞瘤之后第三常见的原发性脑肿瘤。多年来，治疗标准一直是最大安全切除（MSR），然后进行放疗（RT）。这些肿瘤也已知对基于烷化剂的化疗敏感，特别是具有1p/19q共缺失特征的亚组。有确凿数据表明，这些肿瘤在复发或进展情况下对化疗有反应。最近，术前化疗已被添加到标准的术后放疗中。已发现具有1p/19q共缺失的AO/AOA亚组对添加化疗的反应非常好。在中位总生存期（OS）和中位无进展生存期（PFS）方面的这种显著益处引发了基于分子特征标志物对AO/AOA进行个性化治疗的兴趣。
